Navigation Links
InterMune Reports Results from Triple Combination Study of ITMN-191
Date:1/12/2009

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. InterMune to Present at Thomas Weisel Partners Healthcare Conference
2. Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
3. InterMune to Present at the 2008 Wachovia Healthcare Conference
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
6. Allscripts Reports Fiscal 2009 Second Quarter Results
7. MDS Reports Final Fourth-Quarter 2008 Results
8. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
9. Cardium Reports on Exchange Listing With NYSE Alternext US
10. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
11. Joint Commission Reports Positive Survey Results for CHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... treatments targeting growth factor, researchers say , , SUNDAY, ... cancer cells from the main tumor to other parts ... known as TGFb, which may prove a promising target ... researchers say. , Previous studies have shown that TGFb ... movement. In this new study, a team from Cancer ...
(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...
(Date:12/5/2009)... a phase 1/2 clinical trial that it is ... newly diagnosed with multiple myeloma, a cancer of white ... Cancer Institute. , Partial responses or better were seen ... drug combination in the multi-center study, with 74 percent ... phase 2 population, reports Paul G. Richardson, MD, of ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
(Date:12/5/2009)... MAMA campaign is a collaborative effort by the ... Alliance of North America (MANA), Citizens for Midwifery ... American Registry of Midwives (NARM), and the Midwifery ... recent the efforts of The MAMA Campaign to ...
Breaking Medicine News(10 mins):Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4
... but safety an issue in poorer areas, analysis finds ... million major surgeries are performed worldwide each year, and ... in low-income countries, U.S. researchers report. , Dr. Thomas ... his colleagues defined major surgeries as any incision, excision, ...
... ... when we used Jellyfish Squish we could, see immediate ... ... Ga., June 25 Captain Kevin Carvalho of the,Okaloosa Island ... Officer, but he has never seen a treatment that provided,any ...
... of Sponges and Half of Sinks ... Levels of Illness-Causing Bacteria, PARSIPPANY, N.J., June 25 ... dangerous bacteria, according to a,new international study released today, sponsored ... the United,States and around the world found that 46 percent(2) ...
... Diamond Alignment is quietly revolutionizing the ... Divine...online., NEW YORK, June 25 A quiet ... intimate connection with the,Divine ... online. Diamond Alignment announces ... people around the,world to clear their minds, relax their ...
... -- The Board of,Directors of Golden Meditech ... pleased to announce today that the Company ... management market through the,acquisition of Topshine Hospital ... the largest private haematologist hospitals with,presence in ...
... indicates that despite price inflation, more consumers are ... Texas, June 24 Today, Organic,Alliance, Inc. (Pink Sheets: ... International Exposition and Conference which indicates that,more consumers than ... comes at a time when US Consumer Confidence readings ...
Other Medicine News:Health News:Worldwide Surgery Rates Tied to Economic Status 2Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 2Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 3Health News:Hidden Kitchen Germs Threaten Families 2Health News:Hidden Kitchen Germs Threaten Families 3Health News:Hidden Kitchen Germs Threaten Families 4Health News:Hidden Kitchen Germs Threaten Families 5Health News:Hidden Kitchen Germs Threaten Families 6Health News:Hidden Kitchen Germs Threaten Families 7Health News:Sacred Technology Delivers 'Divine Medicine' Online 2Health News:Golden Meditech Pioneers into China's Hospital Market 2Health News:Golden Meditech Pioneers into China's Hospital Market 3Health News:Golden Meditech Pioneers into China's Hospital Market 4Health News:Latest Research Shows Strong Consumer Demand for Organic Foods 2
(Date:12/4/2009)... Inc., developers of the AcceleDent System , ... announced the availability of a new Continuing Education ... leader in professional education for many industries, including ... patient views about orthodontic treatment, a summary of ...
(Date:12/4/2009)... BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" ... that the US Patent and Trademark Office has allowed ... the initial stages of the manufacture of the Company,s ... are key to the very high concentration of dendritic ...
(Date:12/3/2009)... Systems, a subsidiary of Hill-Rom Holdings, Inc. (NYSE: ... new Allen Amatech(TM) OEM (Original Equipment Manufacturer) business website ... reinforces the Allen Amatech(TM) brand identity and includes an ... descriptions and design specifications for the products. "We hope ...
Breaking Medicine Technology:AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada 14954 1Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada 14954 2Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 1Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 6501 2Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 1Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 2Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 3
... makes proactive choice to elevate hand hygiene measures for ... ... 30 Resurgent,Health and Medical, a leader in automated handwashing ... has ordered 25 CleanTech IC handwashing systems for its locations,in ...
... 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced ... Annual Healthcare Focus Conference on Tuesday, October 7,2008 at ... being held at Le,Parker Meridien in New York City., ... of Anadys,will present an overview of Anadys and its ...
Other Medicine Technology:Resurgent Health and Medical Announces That Children's Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems 2Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference 2
... Nicolet VersaLab is a ... Doppler system for evaluation ... Crisp, clear Doppler sound ... a display and print-out ...
Scoliosis Devices....
... VIASYS Neurocare - continues the ... diagnosis. Exceptional convenience and speed. Superior ... ,VasoGuard delivers features you won't find ... for cuff attachment and testing. Up ...
... The Socon Spinal System is ... components with multiple mounting options. Minimal ... for spondylolisthesis. Solid clamping concept. Monosegmental ... and acceptance with over 8,000 implantations. ...
Medicine Products: